4218. Fluvastatin

Nomenclature

CAS number: 93957-54-1
(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (±)-(3R*,5S*,6E)-7-[3-(p-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate.
C24H26FNO4; mol wt 411.47.
C 70.06%, H 6.37%, F 4.62%, N 3.40%, O 15.55%.

Description and references

Synthetic HMG-CoA reductase inhibitor. Prepn: F. G. Kathawala, WO 8402131; idem, US 4739073 (1984, 1988 both to Sandoz). Manufacturing process: P. C. Fuenfschilling et al., Org. Process Res. Dev. 11, 13 (2007). Clinical pharmacology: J. Yuan et al., Atherosclerosis 87, 147 (1991). Clinical pharmacokinetics: F. L. S. Tse et al., J. Clin. Pharmacol. 32, 630 (1992). Metabolism in humans: J. G. Dain et al., Drug Metab. Dispos. 21, 567 (1993). HPLC determn in plasma: G. Kalafsky et al., J. Chromatogr. 614, 307 (1993). Clinical study in familial hypercholesterolaemia: E. Leitersdorf et al., Eur. J. Clin. Pharmacol. 45, 513 (1993); in prevention of cardiac events following percutaneous coronary intervention: P. W. J. Serruys et al., J. Am. Med. Assoc. 287, 3215 (2002). Review of pharmacology and therapeutic use: R. I. Levy et al., Circulation 87, Suppl. III, III-45III-53 (1993).

Chemical structure

Derivative

Sodium salt.

Nomenclature

CAS number: 93957-55-2
Fluindostatin; XU 62-320; Lescol (Novartis); Lipaxan (Italfarmaco); Primexin (Wander).
C24H25FNNaO4; mol wt 433.45.
C 66.50%, H 5.81%, F 4.38%, N 3.23%, Na 5.30%, O 14.76%.

Properties

White to pale yellow, hygroscopic powder. mp 194-197°. Sol in water, ethanol, methanol.

Therapeutic Category

Antilipemic.

Keywords

Antilipemic; HMG CoA Reductase Inhibitors; HMG CoA Reductase Inhibitor